Prothena (PRTA) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prothena (PRTA) has outperformed YD Bio (YDES) over the past year, losing 16.6% versus a loss of 67.3%. Prothena is the larger company by market cap ($434.8 million vs $413.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRTA | YDES |
|---|---|---|
| Share price | $8.47 | $5.84 |
| Market cap | $434.82M | $413.66M |
| 1-day change | -0.12% | -0.68% |
| YTD return | -11.20% | -51.76% |
| 1-year return | -16.62% | -67.33% |
| 5-year return | -86.64% | — |
| EPS (TTM) | $-0.82 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.80 | $22.00 |
| 52-week low | $7.73 | $1.70 |
| Distance from 52-week high | -28.22% | -73.45% |
| Analyst consensus | none | — |
| Avg. price target upside | +152.66% | — |
| Average volume | 482.01K | 283.39K |
| Shares outstanding | 51.34M | 70.83M |
| Employees | 67 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRTA has outperformed YDES by 50.7 percentage points over the past year.
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
PRTA vs YDES FAQ
Which is bigger, Prothena or YD Bio?
Prothena (PRTA) is larger, with a market capitalization of $434.82M compared with $413.66M for YD Bio (YDES).
Which stock has performed better over the past year, PRTA or YDES?
PRTA returned -16.62% over the past 12 months, compared with -67.33% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Prothena and YD Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Prothena and Medical Specialities for YD Bio.